BioSpace News Archive

Deals

Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

Seattle Genetics is paying $10 per share in cash for Cascadian.

January 31, 2018
·
3 min read
·
Mark Terry
Policy

Trump Endorses ‘Right to Try’ Experimental Drug Bill at State of the Union Address

The bill would allow access to experimental treatments for patients with terminal conditions.

January 31, 2018
·
1 min read
Drug Development

Meet the Unnoticed Alzheimer’s Biotech Facing a Make-or-Break 2018

It seems that the primary news surrounding Alzheimer’s disease research has been nothing but negative for years.

January 31, 2018
·
2 min read
·
Alex Keown
Drug Development

Oncoceutics Release: ONC201 Trial Begins at NYU for Children With H3 K27M Mutant Glioma

Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.

January 31, 2018
·
4 min read
Business

SoCal’s Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs

Vical announced its restructuring late Tuesday.

January 31, 2018
·
2 min read
·
Alex Keown
BioMidwest

Dexcom Beats Abbott in Head-to-Head Glucose Monitoring Trial

The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 minutes.

January 31, 2018
·
1 min read
Drug Development

3 Cases of Brain Damage Force the FDA to Slap a Hold on Bellicum’s Lead Drug

The company is now waiting for the FDA to determine a path forward in resuming clinical studies.

January 31, 2018
·
2 min read
·
Alex Keown
BioMidwest

3 Big Drugmakers With Huge Catalysts on the Horizon

A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect.

January 31, 2018
·
3 min read
·
Mark Terry
Biotech Beach

Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague

MannKind could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today.

January 31, 2018
·
1 min read
Deals

Why AbbVie Could Join the M&A Mania Soon

The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash.

January 31, 2018
·
3 min read
·
Mark Terry